[ad_1]
HONG KONG, Oct. 30, 2022 /PRNewswire/ — Akeso, Biopharma (9926. HK) (“Akeso”) released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC), in an oral presentation at the IASLC 2022 Asia Conference on Lung Cancer.
Preliminary data of AK112 combination with etoposide and carboplatin showed a favorable safety profile and promising anti-tumor efficacy as first-line treatment in patients with ES-SCLC and may be a promising treatment option. Compared to the data from marketed PD-L1 inhibitors in combination with chemotherapy, AK112 in combination with chemotherapy demonstrated superior antitumor efficacy and survival benefit.
As of June 1, 2022all patients had received at least one dose of AK112. The median follow-up time was 7.2 months.
- Median progression-free survival (PFS) was 6.9 months, …
Full story available on Benzinga.com
[ad_2]
Source link
